EODData

MEMBERSHIP REGISTER LOG IN

FRA, LDBA: H. LUNDBECK A/S SER.B DK1

03 Sep 2025
LAST:

5.375

CHANGE:
 0.03		OPEN:
5.375		HIGH:
5.375		ASK:
0.000		VOLUME:
1.4K
CHG(%):
0.46		PREV:
5.400		LOW:
5.375		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
03 Sep 255.3755.3755.3755.3751.4K
02 Sep 255.3805.4005.3805.4001.4K
01 Sep 255.3905.3905.3905.3901.4K
28 Aug 255.4305.4305.4305.4301.4K
27 Aug 255.2205.4205.2205.4201.4K
26 Aug 255.1805.2155.1805.2151.4K
25 Aug 255.3105.3105.3105.3101.4K
22 Aug 255.2355.3505.2355.3151.4K
21 Aug 255.2005.2005.1955.1951.4K
20 Aug 255.1305.2055.1305.2051.4K

COMPANY PROFILE

Name:H. LUNDBECK A/S SER.B DK1
About:H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. The company was founded in 1915 and is headquartered in Valby, Denmark.
Sector:Healthcare
Address:Ottiliavej 9, Valby, Denmark, 2500
Website:https://www.lundbeck.com
ISIN:DK0061804770

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:11.41
DivYield:0.18
Div/Share:0.95
Price to Book:1.65
Price to Sales:0.22
EBITDA:7.107B
Shares:792.43M
Market Cap:4.259B

TECHNICAL INDICATORS

MA5:5.40
MA10:5.33
MA20:5.10
MA50:4.85
MA100:4.71
MA200:5.06
STO9:76.60
STO14:78.85
RSI14:82.93
WPR14:-21.15
MTM14:0.21
ROC14:0.04
ATR:0.09
Week High:5.43
Week Low:5.22
Month High:5.43
Month Low:4.51
Year High:6.60
Year Low:3.68
Volatility:20.70

RECENT DIVIDENDS

Date Amount
27 Mar 2025$0.13
21 Mar 2024$0.09
22 Mar 2023$0.08